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Summary. We compared the acute tubular nephrotoxicity 
of three platinum compounds in children and adults with 
solid tumors by monitoring the urinary excretion of ala- 
nine aminopeptidase, N-acetyl-fl-D-glucosaminidase, and 
total protein. Cisplatin (100 mg/m 2) was administered with 
mannitol, or at a twofold larger total dosage (50 mg/m 2 
per day for 4 days) in a 3% saline infusion. Carboplatin 
(300 mg/m 2) was administered in combination with 5-flu- 
orouracil, and iproplatin was administered in dosages 
ranging from 216 to 388 mg/m 2. Enzymuria and proteinu- 
ria induced by cisplatin at a total dosage of 200 mg/m 2 on 
a divided schedule did not significantly differ from that 
observed for the single 100 mg/m 2 dose. Enzymuria and 
proteinuria induced by carboplatin and iproplatin were 
significantly less than that for cisplatin; however, one pa- 
tient developed chronic tubular damage after three courses 
of carboplatin, and the acute tubular toxicity of iproplatin 
in one of 15 patients was exceptional. Our findings sup- 
port the value of administering cisplatin in hypertonic sa- 
line on a divided schedule as a strategy to reduce acute tu- 
bular damage. Although carboplatin and iproplatin are 
less nephrotoxic than cisplatin, occasionally patients expe- 
rience subclinical acute or chronic tubular damage that 
may lead to overt nephrotoxicity with continued therapy. 
Introduction 
Nephrotoxicity is the dose-limiting side-effect of cisplatin 
[21]. Therapeutic maneuvers to reduce nephrotoxicity in- 
clude intensive parenteral hydration and mannitol-in- 
duced diuresis [14], infusion of cisplatin in a vehicle with a 
high chloride concentration [20, 24, 25], or the administra- 
tion of uroprotective agents [27]. Hydration and diuresis 
reduce the incidence of clinically significant nephrotoxi- 
city at conventional dosages (100 mg/m2), and the use of 
3% saline has led to the administration of high dosages 
(200 mg/m 2) that have proven clinically useful for several 
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tumor types [10, 24, 25]. Numerous platinum analogues 
have been synthesized that may be equally effective at dos- 
ages that are less nephrotoxic. Carboplatin (cis-diamine (1, 
1-cyclobutanedicarboxyatol) platinum, CBDCA, JM8) 
and iproplatin (cis-dichloro-trans-dihydroxy,bis-isopro- 
pylamine platinum IV, CHIP, JM9) are cisplatin ana- 
logues that have been found in phase I - I I  investigational 
trials to be less nephrotoxic than cisplatin by monitoring 
serum creatinine and creatinine clearance rates [3, 7]. 
However, creatinine determination, a reflection of glomer- 
ular filtration, is a relatively insensitive measure of drug- 
induced renal tubular damage. 
Cisplatin-induced nephrotoxicity can be quantitated 
by monitoring urinary markers for tubular cell damage 
[1, 5, 8, 9, 15, 17]. Two widely used markers are urinary al- 
anine aminopeptidase (AAP) and N-acetyl-13-D-glucosam- 
inidase (NAG), high-molecular-mass enzymes that are lo- 
calized within the microvilli and lysosomes of renal tubu- 
lar cells, respectively [2, 18]. After damage to tubular cells, 
these enzymes are released into the urine. Cisplatin in- 
duces acute enzymuria and proteinuria in a sequence con- 
sistent with the development of acute tubular cell necrosis 
[12]. Total urinary protein concentrations increase because 
low-molecular-mass serum proteins are less efficiently 
reabsorbed by dysfunctional tubular cells, and the de- 
nuded tubular epithelium exudes protein [4]. 
We have monitored the relative magnitude of enzymu- 
ria and proteinuria associated with administration of cis- 
platin, carboplatin, and iproplatin. Our primary objectives 
were to evaluate the two cisplatin analogues for acute tu- 
bular nephrotoxicity and to compare the acute tubular 
damage induced by cisplatin in two clinically useful regi- 
mens. 
Methods 
Cisplatin, 100 mg/m 2, was administered over 6 h with pre- 
hydration consisting of 10 g/m 2 mannitol in 500 ml/m 2 5% 
glucose and 0.22% saline to children with solid tumors at 
3 -6  week intervals. These children had serum creatinine 
concentrations < 1 mg/dl and had not received other 
nephrotoxic chemotherapy. 
Adults with head and neck cancer received 200 mg/m 2 
cisplatin (50 mg/m 2 per day for 4 days) at 4-week intervals 
[10]. Each dose was administered over 30-45 min in 
250 ml 3% saline with saline hydration and furosemide di- 
uresis. Urinary chloride concentrations attained during 
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each course ranged from 130 to 230 mEq/1, values similar 
to those reported by Corden et al. [6]. All patients had pre- 
treatment creatinine clearances > 60 ml/min.  
Carboplatin, 300 m g / m  2, was administered i . -v .  over 
30 min to seven adults with head and neck cancer [11]. No 
pretreatment hydration was given. Each dose of  carbo- 
platin was followed by a 5-day continuous infusion of  
5-fluorouracil, 1000 m g / m  2 per day. All patients had an ini- 
tial creatinine clearance > 50 ml /min  and had received no 
prior chemotherapy. 
Iproplatin was administered at 3-week intervals to 15 
children with solid tumors, in dosages ranging from 216 to 
388 m g / m  2 [28]. Each dose was administered in 250 ml 
0.9% saline over 2 h. Although all patients had received 
prior therapy, none had received cisplatin, and all had se- 
rum creatinine concentrations < 1.5 mg/dl .  Two children 
had received abdominal  radiation after unilateral nephrec- 
tomy. Patients were excluded from analysis if they con- 
comitantly received aminoglycosides or amphotericin B. 
Urine specimens were obtained before and daily for 1 
week after administration of  cisplatin, carboplatin, or ip- 
roplatin. Urinary concentrations of  N A G  and AAP were 
determined by modifications of  spectrophotomeric meth- 
ods [13, 16] for automated determinations on a Micro- 
K D A  analyzer (American Monitor  Corp, Indianapolis ,  
Ind). Total urinary protein was measured with Coomassie 
brilliant blue (Bio-Rad Labs, Anaheim, Calif.). Enzyme 
and protein concentrations were expressed relative to the 
consentration of  urinary creatinine to account  for varia- 
tions in urine output. 
For each treatment group, a daily mean concentration 
was calculated for AAP, NAG,  and total protein concen- 
trations for each day beginning on the day before therapy. 
Also, for each course, the average marker concentrations 
were calculated for the 7-day period after drug administra- 
tion. Increases over the pretreatment levels (average mark- 
er concentration minus the pretreatment concentration) 
were used for comparisons of  enzyme and protein excre- 
tion. Values for courses of  100 m g / m  2 cisplatin were com- 
pared to those for each of  the three other regimens by the 
Mann-Whitney test (two-sided), with the significance level 
adjusted by the Bonferonni method [22]. 
R e s u l t s  
We studied ten patients receiving their first two doses of  
cisplatin (100 rag/m2). The daily mean AAP concentration 
increased briskly after cisplatin administration (Fig. 1) and 
remained elevated for 1 week. The daily mean N A G  con- 
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Fig. 1. Daily mean (+SEM) 
concentrations of urinary ala- 
nine aminopeptidase (AAP), 
N-acetyl-fl- D-glucosaminidase 
(NAG), and total protein before 
and after 20 courses of cisplatin 
(100mg/m 2) with mannitol, 5 
courses of cisplatin (50mg/m 2 
per day for 4 days) in hyperton- 
ic saline, 10 courses of carbo- 
platin, and 19 courses of ipro- 
platin. The upper limits of the 
reference range for AAP and 
NAG are 3.0 and 1.1 units/ 
mmol creatinine, and for total 
protein, 20 g/mol creatinine 
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Table 1. Average increases over baseline of urinary enzyme and 
protein excretion ~' 
DRUG NAG AAP Total protein 
Units/mmol Units/mmol g/tool 
creatinine creatinine creatinine 
Mean(_+SD) n Mean(_+SD) n Mean(+SD) n 
Cisplatin 1.10 (0.60) 18 1.61 (1.14) 19 59.79 (49.30) 10 
( 100 mg/m 2) 
Cisplatin 2.39 (1.59) 5 1.40 (0.55) 5 27.42 (42.43) 5 
(200 mg/m ~) 
Carboplatin 0.05* (0.38) 10 0.14" (0.44) 10 2.70* (4.13) 10 
Iproplatin 0.27* (0.90) 18 0.40* (1.78) 18 2.89* (17.54) 18 
*, Values are the average marker concentrations for the 7-day 
period after drug administration minus the pretreatment con- 
centration. Tests for differences of these values between cispla- 
tin (100 mg/m 2) and each of the three other groups were done 
by the Mann-Whitney rank sum test (two-sided), with the signi- 
ficance levels adjusted by the Bonferonni method [22]; 
* P< 0.01, after adjustment 
achieving a peak level by the 4th day after cisplatin admin- 
istration and then slowly declining towards the predose 
level. Total urinary protein excretion lagged behind that 
for NAG,  achieving a peak level 1 week after cisplatin 
treatment. In some instances, AAP and N A G  concentra- 
tions remained persistently elevated up to administration 
of  the next cisplatin dose. However, urinary protein con- 
centrations returned to pretreatment levels. 
We evaluated high-dose cisplatin in three patients re- 
ceiving their first course of  50 m g / m  2 per day for 4 days 
and one patient receiving his first two courses. Daily mean 
concentrations of  AAP, NAG,  and total protein increased 
in unison (Fig. 1), peaking on the day after the last dose of  
cisplatin. Increases in AAP, NAG,  and total protein excre- 
tion over the pretreatment concentration did not signifi- 
cantly differ from those for 100 m g / m  2 cisplatin (Table 1). 
In contrast to cisplatin, carboplatin did not acutely in- 
duce enzymuria or proteinuria (Fig. 1). The average mark- 
er concentrations did not significantly differ from pre- 
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Fig. 2. Comparison of changes in AAP and NAG excretion asso- 
ciated with the four drug regimens. Values shown are the average 
enzyme concentrations for the 7-day period after drug administra- 
tion minus the pretreatment concentration. Dashed line indicates 
no change from pretreatment concentration 
treatment concentrations (Fig. 2) and were significantly 
(P<0.01) lower than those for 1 0 0 m g / m  2 cisplatin 
(Table 1). 
Enzyme and protein excretion associated with ipro- 
platin was also less than that following cisplatin (Table 1); 
however, one patient showed a more than threefold in- 
crease in average marker excretion over pretreatment con- 
centrations (Fig. 2). This child and several others had high 
pretreatment enzyme levels, indicating preexisting renal 
tubular damage that could be ascribed in part to previous 
therapy or advanced disease. As a result of  these increased 
pretreatment levels, total enzyme, but not protein, excre- 
tion was comparable to that for 1 0 0 m g / m  2 cisplatin 
(Fig. 1). However, average marker excretion did not signi- 
ficantly differ from pretreatment levels (Fig. 2). 
Serum creatinine concentrations, measured at least 3 
weeks after therapy, did not significantly differ from pre- 
treatment concentrations for any treatment group. 
Discussion 
Our findings demonstrate that 200 m g / m  2 cisplatin can be 
administered over 4 days without a substantial increase in 
acute nephrotoxicity over that seen for a single 100 m g / m  2 
dose of  cisplatin; this supports the use of  hypertonic saline 
as a strategy to reduce nephrotoxicity. In this study, carbo- 
platin and iproplatin induced negligible acute tubular 
damage at hematologically toxic dosages. These com- 
pounds deserve further investigation to define the spec- 
trum of their therapeutic activity and potential cumulative 
nephrotoxicity and ototoxicity. 
Measurements of  urinary markers of  nephrotoxicity 
may be clinically useful to monitor  acute [1, 5, 8, 9, 15, 17, 
26] and chronic [12] tubular damage. For evaluation of  
acute nephrotoxicity, interpretation of  these measurements 
depends in part upon the timing of  specimen collection. 
For example, Pendyala et al. [26] reported that N A G  
excretion after iproplatin administration did not differ 
from that following cisplatin; however, these investigators 
obtained urine specimens for no more than 8 h after cis- 
platin administration. Figure 1 shows that obtaining speci- 
mens at 8 h is misleading, since N A G  levels do not peak 
until several days after cisplatin administration. 
The paucity of  acute changes in enzymuria after carbo- 
platin and iproplatin administration does not exclude the 
possibility of  chronic renal damage after multiple courses. 
The chronic effect of  retained intracellular species of  plati- 
num compounds  may be more important  than acute tubu- 
lar nephrotoxicity [29]. The renal uptake of  carboplatin 
and iproplatin reportedly does not differ substantially 
from that for cisplatin [19, 23]. Cisplatin induces chronic 
renal tubular damage in most patients, leading to presis- 
tent elevations of  urinary N A G  [12]. We have studied a pa- 
tient who developed severe electrolyte abnormalities and a 
transient decrease in creatinine clearance after three 
courses of  carboplatin. Of interest were chronically elevat- 
ed urinary enzyme levels before the fourth course of  car- 
boplatin at a time when conventional determinations of  
the creatinine clearance rate and serum creatinine were in 
an acceptable range for retreatment. Electrolyte wasting 
and serum creatinine changes also followed the fourth 
course of  carboplatin. 
In addition to the total dosage administered, factors 
that may contribute to acute cisplatin-induced nephrotoxi- 
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city include the peak concentrat ion and total durat ion of 
exposure to the drug. The increase in ur inary AAP concen- 
trations induced by cisplatin on a divided schedule in hy- 
pertonic saline was delayed in comparison to the immedi- 
ate increase observed for the single high-dose cisplatin re- 
gimen (Fig. 1). This could reflect delayed sloughing of 
brush border microvilli, related in part  to a protective ef- 
fect of high ur inary chloride concentrat ions or to lower 
peak cisplatin concentrat ions attained with the divided 
schedule. However, the chloride content  of the vehicle for 
infusion and not the chloruresis itself is reported to ameli- 
orate nephrotoxicity [20]. We are currently evaluating 
acute tubular  nephrotoxicity in relation to the pharmaco- 
kinetics of cisplatin administered as a cont inuous infusion 
versus intermittent  daily bolus. 
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